Watch Ticker

Liquidia Corporation Common Stock

Go to Liquidia Corporation Common Stock Website

$20.01

0.53 (2.72%)

Live

Previous Close

$20.07

Day Range

$19.14 - $20.09

Previous Day Range

$17.82 - $19.955

Market Cap

$1.7 billion USD

Day Vol.

2.8 million

Previous Day Vol.

2.8 million

Currency

USD

Primary Exchange

Nasdaq

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hyperte...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Liquidia Corporation - U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

The U.S. FDA has approved Liquidia's YUTREPIA, an inhaled dry-powder formulation of treprostinil, for the treatment of PAH and PH-ILD. The approval is based on the INSPIRE trial, which demonstrated YUTREPIA's safety, tolerability, and efficacy.

Related tickers: LQDA, UTHR.

Read Full Article

N/A - Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

Liquidia Corporation announced that United Therapeutics filed a complaint alleging infringement of a patent related to inhaled treprostinil. Liquidia stated it has invalidated similar claims in the past and will continue to defend patients' access to its therapy.

Related tickers: LQDA, UTHR.

Read Full Article

Trending Tickers

Please sign in to view